Demonstrates the effective binding of peptides to Clec12a in dendritic cells, suggesting potential for immune treatment.
Clec12a is an immunoregulatory C-type lectin receptor expressed on dendritic cells as well as other myeloid cells, and involved in maintaining immune homeostasis. Unlike many other C-type lectin receptors that promote immune activation, Clec12a transmits inhibitory signals through an immunoreceptor tyrosine-based inhibitory motif, thereby contributing to immune regulation. Although the extracellular domain of murine Clec12a has been produced in previous studies, its suitability as a functional bait for directed evolution–based ligand discovery has not been established, nor have quantitative yield and scalability been reported. Here, we established a mammalian expression system that reproducibly yields ∼80 mg/L of the mClec12a extracellular domain, providing material of sufficient quality and quantity for directed evolution of peptide binders. Incorporation of an interleukin-2 signal peptide enabled efficient secretion from Expi293 cells, and the purified protein retained N- glycosylation, indicating proper maturation through the endoplasmic reticulum-Golgi pathway. Using ribosome display with mClec12a as bait, three mClec12a binding peptides (CBP1-3) were isolated, with CBP2 showing the highest affinity ( K D ≈ 6.29 μM). Importantly, CBP2 bound to primary dendritic cells derived from mouse spleen and bone marrow, supporting the native-like conformation and functional integrity of the recombinant mClec12a used for selection. The identified peptide represents a first-generation mClec12a + cell targeting ligand and provides a foundation for further optimization toward dendritic cell targeting and immunomodulatory applications. • The murine Clec12a was expressed in mammalian cells in a yield of ∼80 mg/L. • The purified protein underwent N -glycosylation as a post-translational modification. • Recombinant Clec12a served as a native-like bait for ribosome display-based peptide screening. • Selected peptides bound to Clec12a-expressing primary dendritic cells. • The results indicated that the native folding of recombinant Clec12a was maintained.
No takes yet. Share an insight, caveat, or question.
Kawaguchi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: